DKSH Hong Kong joined hands with Sumitomo Pharmaceuticals Asia Pacific to support the Hong Kong Schizophrenia Research Society of the University of Hong Kong in organizing the biennial international conference held in September.
Media release
Hong Kong, September 15, 2021 – DKSH Business Unit Healthcare, Asia's leading partner for healthcare companies seeking to grow their business in Asia and beyond, partnered with its longstanding client, Sumitomo Pharmaceuticals Asia Pacific Pte. Ltd. (hereinafter “Sumitomo Pharmaceuticals Asia Pacific”), to become the sponsors for the 7th Asian Congress of Schizophrenia Research (ACSR) under this year's theme: Psychosis Research and Intervention in a Changing World. The virtual congress targeted around 1,000 psychiatrists from Hong Kong – including those from the hospital authority – and around the world.
The two-day congress hosted professors, doctors, and medical experts from Belgium, Canada, China, Germany, Hong Kong, Indonesia, Italy, Japan, Korea, Malaysia, Mongolia, Portugal, the United Kingdom, the United States, Singapore, Taiwan, and Thailand. A series of symposiums were organized to share insights on the subject matters from cognition, psychosis studies and treatment to schizophrenia diagnosis and early intervention.
DKSH Hong Kong and Sumitomo Pharmaceuticals Asia Pacific hadinvited Dr Wai-Song Yeung from Pamela Youde Nethersole, Eastern Hospital, Hong Kong, and Professor Christoph U. Correll from Institute of Behavioral Science, Feinstein Institutes for Medical Research, United States, to discuss in a sponsored symposium on “Early-Onset Schizophrenia – diagnosis, early intervention,and optimization of outcomes”.
Xie Xinyan, Regional Product Manager of Sumitomo Pharmaceuticals Asia Pacific, said: "DKSH Hong Kong is a trusted business partner for us. We are pleased to work with the DKSH team to participate in congresses that will enhance the quality of scientific education for our physicians, thereby benefitting patients in the long term.”
Wai Ting Fong, Head of Management and Vice President of Healthcare, DKSH Hong Kong & Macau, was equally pleased to partner with Sumitomo Pharmaceuticals Asia Pacific for the sponsorship: “DKSH Hong Kong has been very keen to participate and support international healthcare congresses and conventions. Through engaging with the medical practitioners around the world, we can gather and introduce advanced healthcare products, services, and treatments to patients in Hong Kong and Macau.”
For further information, please contact:
DKSH Business Unit Healthcare
Sheena Flannery
Director, Group Communications
Phone +66 2 220 9739
sheena.flannery@dksh.com
DKSH Hong Kong
Astrid Lo
Manager, Branding & Communications
Phone +852 2895 9610
astrid.lo@dksh.com
About Sumitomo Dainippon Pharma
Sumitomo Pharmaceuticals Asia Pacific, as the Singapore subsidiary of Sumitomo Dainippon Pharma in Japan continues the corporate mission to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people in the Asia Pacific region and aims to support Sumitomo Dainippon Pharma to become a global specialized player. The company's area of focus includes research on psychiatry and neurology, oncology, and regenerative medicine and cell therapy. For more details, please visit Sumitomo Dainippon Pharma’s website: www.ds-pharma.com.
About DKSH
DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 32,450 specialists, generating net sales of CHF 10.7 billion in 2020. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 7,970 specialists, the Business Unit generated net sales of CHF 5.4 billion in 2020. www.dksh.com/hec